title: Cementoblasts maintain expression of osteocalcin in the presence of mineral trioxide aggregate.
abstract: This study investigated the effects of mineral trioxide aggregate on cementoblast growth and osteocalcin production in tissue culture. For cellular morphology studies, cementoblasts on mineral trioxide aggregate, IRM, and amalgam were incubated for 48 h then fixed for scanning electron microscopic analysis. For gene expression on mineral trioxide aggregate and IRM, reverse transcriptase polymerase chain reaction was performed using primer sets for glyceraldehyde-3-phosphate dehydrogenase, type I collagen, alkaline phosphatase, osteocalcin, and bone sialoprotein after 3 and 5 days. In vitro matrix protein expression was evaluated by confocal microscopy for the presence of osteocalcin on MTA after 7 and 12 days. Images were compared with controls to assess qualitative differences. Results suggest that mineral trioxide aggregate permits cementoblast attachment and growth and the production of mineralized matrix gene and protein expression. Our data indicates that mineral trioxide aggregate can be considered cementoconductive.
authors.affiliation: State University of New York at Buffalo, NY 14214-3008, USA.
authors.forename: Troy S
authors.initials: TS
authors.lastname: Thomson
authors.forename: Janice E
authors.initials: JE
authors.lastname: Berry
authors.forename: Martha J
authors.initials: MJ
authors.lastname: Somerman
authors.forename: Keith L
authors.initials: KL
authors.lastname: Kirkwood
mesh_terms: D000469:Alkaline Phosphatase / Q000032:analysis; D017607:Aluminum Compounds / Q000494:pharmacology*; D000818:Animals; D017610:Calcium Compounds / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D018929:Cell Culture Techniques; D002455:Cell Division / Q000187:drug effects; D024042:Collagen Type I / Q000032:analysis; D003723:Dental Amalgam / Q000494:pharmacology; D003739:Dental Cementum / Q000187:drug effects* / Q000378:metabolism; D004338:Drug Combinations; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000032:analysis; D058574:Integrin-Binding Sialoprotein; D008768:Methylmethacrylates / Q000494:pharmacology; D051379:Mice; D018613:Microscopy, Confocal; D008855:Microscopy, Electron, Scanning; D015675:Osteocalcin / Q000032:analysis* / Q000096:biosynthesis; D010087:Oxides / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012387:Root Canal Filling Materials / Q000494:pharmacology*; D012795:Sialoglycoproteins / Q000032:analysis; D017640:Silicates / Q000494:pharmacology*; D013997:Time Factors; D015035:Zinc Oxide-Eugenol Cement / Q000494:pharmacology
chemical_list: D017607:Aluminum Compounds; D017610:Calcium Compounds; D024042:Collagen Type I; D004338:Drug Combinations; C546872:Ibsp protein, mouse; D058574:Integrin-Binding Sialoprotein; D008768:Methylmethacrylates; D010087:Oxides; D012387:Root Canal Filling Materials; D012795:Sialoglycoproteins; D017640:Silicates; D015035:Zinc Oxide-Eugenol Cement; C086631:mineral trioxide aggregate; D015675:Osteocalcin; C031667:IRM cement; D003723:Dental Amalgam; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D000469:Alkaline Phosphatase